In a global organization of Gilead Sciences' scale, the challenge isn't just digitalizing—it’s unifying. To truly accelerate the next breakthrough, your data must flow seamlessly across your organization, from biotherapeutics and small molecule development to manufacturing.
BIOVIA offers the only scientific platform engineered to handle this complexity. With BIOVIA you can access a unified digital backbone designed for the specific rigors of drug process development and tech transfer.
While others offer fragmented software, BIOVIA's solution provides a single, compliant environment that bridges the gap between R&D and Manufacturing.
Data is only as good as its structure. Our core strategy integrates Scientific AI across the pharmaceutical lifecycle. By ensuring your data is structured and contextualized at the point of entry, we help Gilead Sciences' boost R&D speed and efficiency, turning months of manual data aggregation into seconds of automated insight.
We understand the nuances of biotherapeutics and small-molecule development. Our platform is designed to:
Eliminate Data Silos
Connect disparate workflows into one cohesive digital thread
Ensure Compliance
Maintain a rigorous, audit-ready environment without sacrificing agility
Accelerate Tech Transfer
Standardize process definitions to move molecules from the lab to the plant faster than ever before
BIOVIA is uniquely equipped to optimize Gilead Sciences' complex requirements. We stand alone in our ability to provide a scientific digital platform that supports the entire molecule-to-manufacturing lifecycle within a single, compliant environment.